Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEANUT: Pembrolizumab and Nab-Paclitaxel in Metastatic Urothelial Carcinoma
NCT03464734Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jan 2019
- Primary completion
- Jan 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, paclitaxel in urothelial carcinoma (UC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Started Jan 2019; status: completed.
02
Drugs
pembrolizumabpaclitaxel
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03464734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03464734.